On track to define optimal dosing interval and advance manufacturing scale up of REYOBIQ for pivotal trial readiness in late ...

Investing.com -- Plus Therapeutics Inc (NASDAQ:PSTV) stock dropped 3.5% on Thursday following the company’s announcement of a Type B meeting with the FDA regarding its REYOBIQ pivotal trial strategy ...

We recently published a list of 10 Micro-, Small-Cap Firms Dominate Thursday’s Gains. In this article, we are going to take a look at where Plus Therapeutics Inc. (NASDAQ:PSTV) stands against other ...

Plus Therapeutics Inc. Annual stock financials by MarketWatch. View the latest PSTV financial statements, income statements and financial ratios.

Plus Therapeutics Inc (NASDAQ:PSTV) shares are trading higher by 244% to $1.75 during Thursday’s session after the company announced that the FDA accepted the name REYOBIQ for the company’s lead asset ...

Fintel reports that on October 6, 2025, Ascendiant Capital maintained coverage of Plus Therapeutics (NasdaqCM:PSTV) with a Buy recommendation. Analyst Price Forecast Suggests 1,132.22% Upside As of ...

We recently published Massive Gains: 10 Stocks Investors Can’t Stop Buying. Plus Therapeutics Inc. (NASDAQ:PSTV) is one of the top performers on Thursday. Shares of Plus Therapeutics soared by 39.29 ...

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company’s lead ...